Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts

Although histone deacetylase inhibitors (HDACi) are a promising class of anti-cancer drugs, thus far, they have been unsuccessful in early phase clinical trials for pancreatic ductal adenocarcinoma (PDAC). One potential reason for their poor efficacy is the tumor stroma, where cancer-associated fibr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Nguyen, Andrew H., Elliott, Irmina A., Wu, Nanping, Matsumura, Cynthia, Vogelauer, Maria, Attar, Narsis, Dann, Amanda, Ghukasyan, Razmik, Toste, Paul A., Patel, Sanjeet G., Williams, Jennifer L., Li, Luyi, Dawson, David W., Radu, Caius, Kurdistani, Siavash K., Donahue, Timothy R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5386671/
https://ncbi.nlm.nih.gov/pubmed/27894105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13572
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi